公开(公告)号：US20250084096A1

公开(公告)日：2025-03-13

申请号：US18913161

申请日：2024-10-11

Applicant: Genentech, Inc.

Inventor： Robert Anthony BLAKE ,  Peter DRAGOVICH ,  Lewis J. GAZZARD ,  Susan KAUFMAN ,  Tracy KLEINHEINZ ,  Thomas PILLOW ,  Steven T. STABEN ,  Binqing WEI

IPC: C07D495/14 ,  A61P35/00 ,  C07D495/16

Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.

公开(公告)号：US20190263793A1

公开(公告)日：2019-08-29

申请号：US16140392

申请日：2018-09-24

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle BRAUN ,  Emily HANAN ,  Steven T. STABEN ,  Robert Andrew HEALD ,  Calum MACLEOD ,  Richard ELLIOTT

IPC: C07D413/14 ,  C07D267/08 ,  A61K31/553 ,  C07D498/04

Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

公开(公告)号：US20210246129A1

公开(公告)日：2021-08-12

申请号：US17075583

申请日：2020-10-20

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle BRAUN ,  Emily HANAN ,  Steven T. STABEN ,  Robert Andrew HEALD ,  Calum MACLEOD ,  Richard ELLIOTT

IPC: C07D413/14 ,  C07D498/04 ,  A61K31/553 ,  C07D267/08

Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

公开(公告)号：US20210221821A1

公开(公告)日：2021-07-22

申请号：US17198240

申请日：2021-03-10

Applicant: Genentech, Inc.

Inventor： Robert Anthony BLAKE ,  Peter DRAGOVICH ,  Lewis J. GAZZARD ,  Susan KAUFMAN ,  Tracy KLEINHEINZ ,  Thomas PILLOW ,  Steven T. STABEN ,  Binqing WEI

IPC: C07D495/14 ,  C07D495/16 ,  A61P35/00

Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.